Literature DB >> 18694622

Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer.

Jinyun Chen1, Ann M Killary, Subrata Sen, Christopher I Amos, Douglas B Evans, James L Abbruzzese, Marsha L Frazier.   

Abstract

p21 and p27, members of the kinase inhibitor protein (KIP) family, bind to cyclin-CDK complexes to inhibit their catalytic activity and induce cell cycle arrest. The purpose of our study was to identify whether the p21 (C-to-A), and p27 (T-to-G) polymorphisms were associated with age at diagnosis of pancreatic cancer, either independently or jointly. Two hundred and five patients with a diagnosis of pancreatic cancer were genotyped for the p21 and p27 polymorphisms. We found patients with the p21 variant genotype (CA/AA) had an earlier age at diagnosis than those with the wild-type genotype (CC) (log-rank, P=0.001; HR=1.89; 95%CI, 1.28-2.78). The p21 and p27 polymorphisms combined had a joint effect on age-associated risk for early diagnosis of pancreatic cancer (log-rank, P=0.004; HR=2.91; 95%CI, 1.49-5.67). Our findings suggest that the p21 polymorphism independently and p21 and p27 polymorphisms jointly contribute to a significantly earlier age at diagnosis of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18694622      PMCID: PMC3780599          DOI: 10.1016/j.canlet.2008.06.022

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  24 in total

1.  No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk.

Authors:  Li Su; Geoffrey Liu; Wei Zhou; Li Lian Xu; David P Miller; Sohee Park; Thomas J Lynch; John C Wain; David C Christiani
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-02       Impact factor: 4.254

Review 2.  New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

Authors:  Olivier Coqueret
Journal:  Trends Cell Biol       Date:  2003-02       Impact factor: 20.808

3.  Waf-1 (p21) and p53 polymorphisms in breast cancer.

Authors:  Channa Keshava; Bonnie L Frye; Mary S Wolff; Erin C McCanlies; Ainsley Weston
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-01       Impact factor: 4.254

4.  An overview of the cell cycle arrest protein, p21(WAF1).

Authors:  K Harada; G R Ogden
Journal:  Oral Oncol       Date:  2000-01       Impact factor: 5.337

Review 5.  Pancreatic cancer biology and genetics.

Authors:  Nabeel Bardeesy; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

6.  CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma.

Authors:  Adam S Kibel; Brian K Suarez; Jay Belani; Joe Oh; Raul Webster; Michele Brophy-Ebbers; Chan Guo; William J Catalona; Joel Picus; Paul J Goodfellow
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

7.  p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer.

Authors:  Ju Won Roh; Jae Weon Kim; Noh Hyun Park; Yong Sang Song; In Ae Park; Sang-Yoon Park; Soon Beom Kang; Hyo Pyo Lee
Journal:  Gynecol Oncol       Date:  2004-05       Impact factor: 5.482

8.  A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer.

Authors:  Bao-li Chang; Siqun L Zheng; Sarah D Isaacs; Kathy E Wiley; Aubrey Turner; Ge Li; Patrick C Walsh; Deborah A Meyers; William B Isaacs; Jianfeng Xu
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma.

Authors:  Guojun Li; Erich M Sturgis; Li-E Wang; Robert M Chamberlain; Margaret R Spitz; Adel K El-Naggar; Waun K Hong; Qingyi Wei
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

10.  Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan.

Authors:  C M Shih; P T Lin; H C Wang; W C Huang; Y C Wang
Journal:  Jpn J Cancer Res       Date:  2000-01
View more
  6 in total

1.  Polymorphisms in UGT2B4 and susceptibility to pancreatic cancer.

Authors:  Xu Che; Dianke Yu; Zongyong Wu; Jianwei Zhang; Yintai Chen; Yaling Han; Chenfeng Wang; Jun Qi
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 2.  p27(Kip1) V109G polymorphism and cancer risk: a systematic review and meta-analysis.

Authors:  Feng Wei; Jin Xu; Lin Tang; Jiaqing Shao; Yucai Wang; Longbang Chen; Xiaoxiang Guan
Journal:  Cancer Biother Radiopharm       Date:  2012-07-23       Impact factor: 3.099

3.  Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck.

Authors:  Dapeng Lei; Erich M Sturgis; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

4.  Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1.

Authors:  Luisa Circelli; Valeria Ramundo; Vincenzo Marotta; Concetta Sciammarella; Francesca Marciello; Michela Del Prete; Lina Sabatino; Daniela Pasquali; Francesco Izzo; Stefania Scala; Annamaria Colao; Antongiulio Faggiano; Vittorio Colantuoni
Journal:  J Cell Mol Med       Date:  2015-03-30       Impact factor: 5.310

5.  Identification of genetic variants predictive of early onset pancreatic cancer through a population science analysis of functional genomic datasets.

Authors:  Jinyun Chen; Xifeng Wu; Yujing Huang; Wei Chen; Randall E Brand; Ann M Killary; Subrata Sen; Marsha L Frazier
Journal:  Oncotarget       Date:  2016-08-30

Review 6.  Genetic Association Between CDKN1B rs2066827 Polymorphism and Susceptibility to Cancer.

Authors:  Yongchao Lu; Kejian Gao; Miao Zhang; Aiyan Zhou; Xiaoming Zhou; Zhongan Guan; Xuewen Shi; Shujian Ge
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.